Vitreous samples were studied using a multiplex immunoassay system (MSD Multi-Spot Assay System; Meso Scale Discovery, Gaithersburg, MD, USA). In total, 29 different inflammatory mediators were analyzed for each vitreous sample. The Chemokine Panel 1 (human) kit was used to measure eotaxin, eotaxin-3, IL-8, interferon-γ–induced protein-10 (IP-10), monocyte chemotactic protein-1 (MCP-1), MCP-4, macrophage derived chemokine (MDC), macrophage inflammatory protein [MIP]–1α, MIP-1β, and thymus activation regulated chemokine (TARC). Cytokine Panel 1 (human) was used to measure granulocyte-macrophage colony–stimulating factor (GM-CSF) IL-1α, IL-12/IL-23p40, IL-15, IL-16, IL-17A, IL-5, IL-7, TNF-β, and VEGF. Proinflammatory Panel 1 (human) was used to measure IFN-γ, IL-1β, IL-10, IL-12p70, IL-13, IL-2, IL-4, IL-6, IL-8, and TNF-α.
Cryopreserved vitreous samples as well as all kit components were brought to room temperature before analysis. Reverse pipetting was applied in all pipetting steps to avoid bubbles. Samples were spun at 2000
g for 20 minutes to remove cell debris and aggregates and diluted 2-fold in sample diluent. The analyses were performed according to the instructions from the manufacturer (Meso Scale Discovery). Briefly, duplicates of diluted calibrator and samples were loaded on the plate and the plate was incubated on a shaker for 2 hours. After washing, labeled detection antibodies were pipetted in the wells and the plate was incubated for another 2 hours. After incubation, the plate was washed and read buffer was added to the plate just before reading in the MESO QuickPlex SQ 120 instrument using the MSD DISCOVERY WORKBENCH analysis software. Curve fitting was done with the same software using a four-parameter logistic model with a 1/Y
2 weighting according to the manufacturer's instructions, and concentrations were determined from the standard curves. The lower limit of detection (LLOD) was the calculated concentration corresponding to the average signal 2.5 standard deviations above the background (zero calibrator) for each analysis. All measurements were performed using one batch of reagents by board-certified laboratory technicians who were blinded to clinical data. Only inflammatory mediators for which at least 90% of the duplicate samples were in detection range were included in the statistical evaluation. A total of 14 out of 29 analyzed factors fulfilled this criterion. A list of the inflammatory immune mediators that were in detection range and those that were not is presented in
Table 1.